Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.


Read More

An empty grocery cart in a market.

NYC Mayor Zohran Mamdani proposes five city-run grocery stores. See the arguments for and against, from food deserts to bodega concerns and the $70M cost.

Getty Images, Kwangmoozaa

Government-Owned Grocery Stores: Accessible Nutrition or Government Overreach?

Issue Introduction

Over the past few years, affordability has become the most central issue affecting Americans and the quality of life in the United States. The prices of groceries and basic necessities have risen 25-30% since the COVID-19 pandemic and are projected to rise another 3.2% in 2026. At the same time, the exodus of grocery chains from rural and low-income areas has scattered food deserts throughout individual states. Recent mass closures include Grocery Outlet’s shuttering of 36 stores and continued shut-downs of many Albertsons locations. These factors have led politicians to make affordability a major campaign issue.

During his progressive campaign for mayor of New York City, Zohran Mamdani raised the idea of opening grocery stores owned and operated by the city government to provide New Yorkers with affordable groceries. In his April 2026 public address that marked his first 100 days in office, Mayor Mamdani announced plans for the first of five city-run grocery stores. Mamdani’s proposed initiative will use $70 million in capital funding to build five city-owned municipal stores–one in each borough–and place them under control of the New York City Economic Development Corporation (NYCEDC). NYCEDC will then select third-party operating staff in accordance with city standards for affordability and proper labor practices. Public opinion following the announcement continues to be divided between uproar and support.

Keep ReadingShow less
Land of the Free, Home of the Capitalism Didn’t Fail America. America Failed to Moderate Capitalism
Monopoly's mr. monopoly in a graffiti collage
Photo by Artur Ament on Unsplash

Land of the Free, Home of the Capitalism Didn’t Fail America. America Failed to Moderate Capitalism

The signs are everywhere. For many Americans, buying power has improved only modestly despite decades of economic growth. Corporate profits are at an all-time high. We have reached a level of wealth inequality last seen almost a hundred years ago. By many measures, our capitalist economy seems to have failed to deliver broadly shared prosperity.

However, the failure isn’t with the free market as an economic approach. Instead, it’s our failure to regulate and moderate the free market, or more accurately, that we have spent 40 years undermining or removing the regulations of the New Deal that made our economy work for more Americans.

Keep ReadingShow less
Woman putting savings in a white piggy bank.

America’s economy now rewards asset ownership over wages. A policy proposal: a $35,000 Birthright Account for every child, and how it could be funded.

Guido Mieth/Getty Images

The American Dream Needs a New Economic Operating System

It is, by now, not an exaggeration to state that the traditional American Dream—work hard, buy a house, raise a family, and retire securely—is failing. It was built for a labor-based economy in which steadily rising wages allowed ordinary families to accumulate wealth. But America has become an asset-based economy, and ownership of those assets is extraordinarily concentrated.

Since the 1980s, the returns from capital have far outpaced the returns from labor. Inflation-adjusted wages for ordinary workers have risen only modestly, while the real value of equities has multiplied many times over. Housing, education, healthcare and childcare costs have soared, employment has become less secure, and defined-benefit pensions have largely disappeared. Even two-income households with respectable jobs often struggle to buy a home, build savings and accumulate enough for retirement.

Keep ReadingShow less